Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 3.63
EIGR's Cash-to-Debt is ranked lower than
71% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. EIGR: 3.63 )
Ranked among companies with meaningful Cash-to-Debt only.
EIGR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.88  Med: 9 Max: No Debt
Current: 3.63
0.88
No Debt
Debt-to-Equity 0.41
EIGR's Debt-to-Equity is ranked lower than
84% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. EIGR: 0.41 )
Ranked among companies with meaningful Debt-to-Equity only.
EIGR' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.06  Med: 0.36 Max: 1.19
Current: 0.41
-1.06
1.19
Debt-to-EBITDA -0.55
EIGR's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. EIGR: -0.55 )
Ranked among companies with meaningful Debt-to-EBITDA only.
EIGR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.7  Med: -0.37 Max: -0.05
Current: -0.55
-6.7
-0.05
Piotroski F-Score: 3
Altman Z-Score: 0.77
WACC vs ROIC
9.70%
896.32%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -162.03
EIGR's ROE % is ranked lower than
88% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. EIGR: -162.03 )
Ranked among companies with meaningful ROE % only.
EIGR' s ROE % Range Over the Past 10 Years
Min: -264.76  Med: -87.02 Max: -14.36
Current: -162.03
-264.76
-14.36
ROA % -85.41
EIGR's ROA % is ranked lower than
85% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. EIGR: -85.41 )
Ranked among companies with meaningful ROA % only.
EIGR' s ROA % Range Over the Past 10 Years
Min: -142  Med: -76 Max: -2.75
Current: -85.41
-142
-2.75
ROC (Joel Greenblatt) % -45394.87
EIGR's ROC (Joel Greenblatt) % is ranked lower than
94% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. EIGR: -45394.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
EIGR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -79311.11  Med: -17579.1 Max: -283.1
Current: -45394.87
-79311.11
-283.1
3-Year EBITDA Growth Rate 15.50
EIGR's 3-Year EBITDA Growth Rate is ranked higher than
64% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. EIGR: 15.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
EIGR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 15.5  Med: 31 Max: 57.1
Current: 15.5
15.5
57.1
3-Year EPS without NRI Growth Rate 14.70
EIGR's 3-Year EPS without NRI Growth Rate is ranked higher than
62% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. EIGR: 14.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
EIGR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -8.1 Max: 73.2
Current: 14.7
0
73.2
GuruFocus has detected 2 Warning Signs with Eiger BioPharmaceuticals Inc EIGR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EIGR's 30-Y Financials

Financials (Next Earnings Date: 2018-11-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

EIGR Guru Trades in Q3 2017

Jim Simons 79,013 sh (+237.30%)
» More
Q4 2017

EIGR Guru Trades in Q4 2017

Jim Simons 97,013 sh (+22.78%)
» More
Q1 2018

EIGR Guru Trades in Q1 2018

Jim Simons 164,029 sh (+69.08%)
» More
Q2 2018

EIGR Guru Trades in Q2 2018

Pioneer Investments 7,000 sh (New)
Jim Simons 230,229 sh (+40.36%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:EIGR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Eiger BioPharmaceuticals Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:OTCPK:CYDY, FRA:PB9, NAS:KRYS, NAS:LPTX, ROCO:4193, TSE:4572, OSTO:MVIR B, OTCPK:NWBO, TPE:1733, NAS:KALV, LSE:DDDD, XPAR:GNRO, OSL:TRVX, NAS:OPHT, ASX:MDC, TSX:APS, NAS:MACK, XMCE:ORY, NAS:CDTX, NAS:TRVN » details
Traded in other countries:72C1.Germany,
Headquarter Location:USA
Eiger BioPharmaceuticals Inc is a clinical stage biopharmaceutical company. It is focused on bringing to market novel product candidates for the treatment of orphan diseases.

Eiger BioPharmaceuticals Inc is a clinical stage biopharmaceutical company. It is focused on bringing to market novel product candidates for the treatment of orphan diseases. The company's pipeline includes five Phase 2 development programs addressing four distinct orphan diseases. The pipeline includes lonafarnib for Hepatitis Delta Virus, or HDV, PEG-interferon lambda-1a (lambda) for HDV, exendin 9-39 for Post-Bariatric Hypoglycemia, or PBH and ubenimex for Pulmonary Arterial Hypertension, or PAH and lymphedema.

Ratios

vs
industry
vs
history
PB Ratio 2.30
EIGR's PB Ratio is ranked lower than
69% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. EIGR: 2.30 )
Ranked among companies with meaningful PB Ratio only.
EIGR' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 12.37
Current: 2.3
0
12.37
EV-to-EBIT -2.68
EIGR's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. EIGR: -2.68 )
Ranked among companies with meaningful EV-to-EBIT only.
EIGR' s EV-to-EBIT Range Over the Past 10 Years
Min: -3.97  Med: 0 Max: 0
Current: -2.68
-3.97
0
EV-to-EBITDA -2.68
EIGR's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. EIGR: -2.68 )
Ranked among companies with meaningful EV-to-EBITDA only.
EIGR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.97  Med: 0 Max: 0
Current: -2.68
-3.97
0
Current Ratio 8.49
EIGR's Current Ratio is ranked higher than
51% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. EIGR: 8.49 )
Ranked among companies with meaningful Current Ratio only.
EIGR' s Current Ratio Range Over the Past 10 Years
Min: 0.65  Med: 11.07 Max: 21.2
Current: 8.49
0.65
21.2
Quick Ratio 8.49
EIGR's Quick Ratio is ranked higher than
53% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. EIGR: 8.49 )
Ranked among companies with meaningful Quick Ratio only.
EIGR' s Quick Ratio Range Over the Past 10 Years
Min: 0.65  Med: 11.07 Max: 21.2
Current: 8.49
0.65
21.2

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -88.60
EIGR's 3-Year Average Share Buyback Ratio is ranked lower than
93% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. EIGR: -88.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EIGR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -200.4  Med: -145.35 Max: -88.6
Current: -88.6
-200.4
-88.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.38
EIGR's Price-to-Net-Cash is ranked higher than
50% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. EIGR: 2.38 )
Ranked among companies with meaningful Price-to-Net-Cash only.
EIGR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.71  Med: 3.3 Max: 8.15
Current: 2.38
0.71
8.15
Price-to-Net-Current-Asset-Value 2.31
EIGR's Price-to-Net-Current-Asset-Value is ranked lower than
53% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. EIGR: 2.31 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
EIGR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.69  Med: 3.22 Max: 7.91
Current: 2.31
0.69
7.91
Price-to-Tangible-Book 2.29
EIGR's Price-to-Tangible-Book is ranked lower than
62% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. EIGR: 2.29 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EIGR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.69  Med: 3.2 Max: 7.77
Current: 2.29
0.69
7.77
Earnings Yield (Greenblatt) % -37.40
EIGR's Earnings Yield (Greenblatt) % is ranked lower than
85% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. EIGR: -37.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EIGR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3847.09  Med: 0 Max: 0
Current: -37.4
-3847.09
0

More Statistics

EPS (TTM) $ -3.85
Beta1.08
Volatility87.83%
52-Week Range $7.46 - 18.00
Shares Outstanding (Mil)14.24

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -3.21 -3.12 -2.77
EPS without NRI ($) -3.21 -3.12 -2.77
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}